New Triple-Threat attack on tough leukemia
NCT ID NCT07133997
Summary
This early-stage study is testing the safety and effectiveness of a new three-drug combination for adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or not responded to prior treatments. The treatment combines a cancer-starving enzyme, a drug that blocks a cancer survival protein, and an immunotherapy that helps the immune system target cancer cells. The main goals are to find the safest dose and see if this combination can put the cancer into remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.